With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
Looking for a clear answer on how to treat locally-advanced endometrial cancer? Preliminary results of the long-awaited GOG 258 were presented this week at ASCO. The verdict: keep looking. 813 patients with stage III/IVA endometrioid or stage I/II serous or clear cell carcinoma were randomized post-op to volume-based radiation with concurrent cisplatin -> carbo/Taxol x 4 versus carbo/Taxol x 6 alone. With a median follow-up of 47 months there was no difference in recurrence-free survival (primary endpoint) or toxicities. In more (utterly unsurprising) news, combined chemoradiation significantly reduced loco-regional recurrence and chemotherapy alone (to a higher cumulative dose) significantly reduced distant recurrence. Nothing significantly reduced the advanced endometrial cancer debate.